- 1 day ago
In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor
CEO Hervé Hoppenot describes the strategy for Incyte's PD1, and developing the CDK2 for ovarian and endometrial cancers, and possibly...
- 1 day ago
Bicycle Therapeutics CEO Kevin Lee highlights the company's data at the 2024 ESMO Congress
He discusses data from the Nectin-4 targeting zelenectide pevedotin program, Nectin-4 + CD137, and EphA2.
- 2 days ago
The founder of Entos Pharmaceuticals describes trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens
John Lewis describes the limitations of AAV and LNPs, and how the Entos construct is meant overcome them. Plus, a summary of the...
.png){kind=logo}
.png){kind=logo}